ALPMF (Astellas Pharma) Cyclically Adjusted FCF per Share: $0.80 (As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $14.15
GF Value $14.19
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Cyclically Adjusted FCF per Share?

Astellas Pharma ALPMF 73 Cyclically Adjusted FCF per Share is $0.80 as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.19 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Astellas Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.647. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.80 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted FCF Growth Rate was 16.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Astellas Pharma was 10.80% per year. The lowest was 2.70% per year. And the median was 7.70% per year.

As of today (2026-07-04), Astellas Pharma's current stock price is $14.15. Astellas Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $0.80. Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is 17.69.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 11.83. And the median was 20.39.


Astellas Pharma  (OTCPK:ALPMF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=14.15/0.80
=17.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Astellas Pharma was 28.14. The lowest was 11.83. And the median was 20.39.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Astellas Pharma Cyclically Adjusted FCF per Share Related Terms


Astellas Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Cyclically Adjusted FCF per Share Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 0.77 0.69 0.72 0.80

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.74 0.81 0.76 0.80

ALPMF vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted Price-to-FCF falls into.


ALPMF
73GF Score
Astellas Pharma Inc ALPMF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.647/112.7000*112.7000
=0.647

Current CPI (Mar. 2026) = 112.7000.

Astellas Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.043 98.100 0.049
201609 0.273 98.000 0.314
201612 0.331 98.400 0.379
201703 0.157 98.100 0.180
201706 0.233 98.500 0.267
201709 0.203 98.800 0.232
201712 0.383 99.400 0.434
201803 0.404 99.200 0.459
201806 0.125 99.200 0.142
201809 0.304 99.900 0.343
201812 0.353 99.700 0.399
201903 0.176 99.700 0.199
201906 -0.015 99.800 -0.017
201909 0.357 100.100 0.402
201912 0.217 100.500 0.243
202003 0.152 100.300 0.171
202006 -0.058 99.900 -0.065
202009 0.426 99.900 0.481
202012 0.489 99.300 0.555
202103 0.313 99.900 0.353
202106 0.099 99.500 0.112
202109 0.349 100.100 0.393
202112 0.276 100.100 0.311
202203 0.143 101.100 0.159
202206 0.125 101.800 0.138
202209 0.266 103.100 0.291
202212 0.210 104.100 0.227
202303 0.358 104.400 0.386
202306 -0.016 105.200 -0.017
202309 0.038 106.200 0.040
202312 0.123 106.800 0.130
202403 0.193 107.200 0.203
202406 -0.042 108.200 -0.044
202409 0.188 108.900 0.195
202412 0.043 110.700 0.044
202503 0.333 111.100 0.338
202506 0.151 111.700 0.152
202509 0.732 112.000 0.737
202512 0.205 113.000 0.204
202603 0.647 112.700 0.647

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.80 mean?
Astellas Pharma (ALPMF) has a Cyclically Adjusted FCF per Share of $0.80 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Cyclically Adjusted FCF per Share too high?
Astellas Pharma's current Cyclically Adjusted FCF per Share is $0.80. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
Astellas Pharma's Cyclically Adjusted FCF per Share of $0.80 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Cyclically Adjusted FCF per Share is $0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $14.15 — trading 0.3% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $0.80. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Cyclically Adjusted FCF per Share is $0.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $14.15 is trading 0.3% below its estimated GF Value™ of $14.19. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Cyclically Adjusted FCF per Share: $0.80
  • GF Value™: $14.19 vs. price of $14.15 (0.3% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.15
Price
$14.19
GF Value